KREBS BIOCHEMICALS & INDUSTRIES LTD.-$

Krebs Biochemicals & Industries Ltd has announced that its Board of Directors will convene on August 6, 2026. The primary agenda item is to consider and approve the unaudited financial results for the first quarter ended June 30, 2026. Concurrently, the company reaffirmed its trading window closure for insiders, which began on June 30, 2026, and will remain shut until 48 hours post the declaration of these financial results, as per SEBI regulations.

Krebs Biochemicals & Industries Ltd announced that its Board of Directors has approved a Scheme of Amalgamation with Ipca Laboratories Limited. The merger, subject to regulatory approvals, is set to take effect from April 1, 2026. The rationale includes achieving operational synergies, cost optimization, and consolidating businesses. Krebs Biochemicals, which has incurred continuous losses, possesses manufacturing capabilities for fermentation-based APIs that Ipca Laboratories lacks, potentially enabling Ipca to develop new APIs and secure supply chains for key intermediates. The transaction is considered a related party transaction but will be conducted at arm's length. No cash consideration will be paid; Ipca will issue 7 equity shares for every 200 shares of Krebs Biochemicals.

Krebs Biochemicals & Industries Ltd announced that its Board of Directors has approved a Scheme of Amalgamation with Ipca Laboratories Limited. The merger, subject to regulatory approvals, is set to take place under Sections 230-232 of the Companies Act, 2013. The appointed date for the scheme is April 1, 2026. The rationale includes achieving operational synergies, cost optimization, consolidation of business, and leveraging Krebs' fermentation-based API manufacturing capabilities. Ipca Laboratories reported a standalone audited total income of ₹7431 Crores for FY26, while Krebs Biochemicals had an income of ₹26 Crores, primarily from conversion charges. The transaction is considered a related party transaction but will be conducted at arm's length. There will be no cash consideration; instead, Ipca Laboratories will issue 7 equity shares for every 200 shares of Krebs Biochemicals.

Krebs Biochemicals & Industries Ltd has announced the closure of its trading window for the quarter ended June 30, 2026. This closure, effective from the close of business hours on June 30, 2026, is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The window will remain shut until 48 hours after the declaration of the unaudited financial results for the first quarter. The specific date for the Board meeting to consider these results will be communicated separately to the stock exchanges.

Krebs Biochemicals & Industries Ltd reported audited financial results for the year ended March 31, 2026. The Board of Directors approved the results at a meeting held on May 21, 2026. Revenue from Operations stood at ₹2,373.16 lacs, while the company reported a loss before tax of ₹1,693.31 lacs. The Statutory Auditors issued an unmodified report on the financial statements. The Vizag manufacturing unit remains closed following an order from the Andhra Pradesh Pollution Control Board.

Krebs Biochemicals & Industries Ltd's board meeting on May 21, 2026, approved the audited financial results for the year ended March 31, 2026. The company reported a net loss before tax of ₹1,693.31 lacs for the year ended March 31, 2026, compared to a loss of ₹2,692.40 lacs in the previous year. Revenue from operations stood at ₹2,373.16 lacs, down from ₹4,331.19 lacs in the previous year. The meeting commenced at 11:30 am and concluded at 1:20 pm.

Krebs Biochemicals & Industries Ltd has scheduled a Board of Directors meeting on May 21, 2026, to consider and approve the audited financial results for the fourth quarter and financial year ended March 31, 2026. The trading window for insiders has been closed since March 31, 2026, and will remain closed until 48 hours after the declaration of the results.

Krebs Biochemicals & Industries Ltd responded to an email from the BSE regarding significant movement in its security price. The company clarified that there is no material information or event requiring disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, that, in its opinion, has a bearing on the stock's price movement. The company further stated that it regularly disseminates relevant information and details in compliance with SEBI regulations.

Krebs Biochemicals & Industries Ltd. has announced the closure of the trading window for the consideration of audited financial results for the 4th quarter and year ended 31.03.2026. This closure is in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015. The trading window will be closed for promoters, directors, designated persons, their immediate relatives, and all connected persons covered under the code from the close of business hours on March 31, 2026, until 48 hours after the declaration of the Audited Financial Results for the 4th quarter and year ended March 31, 2026. The date of the Board meeting for the consideration of the said Audited Financial Results will be intimated to the stock exchanges in due course of time.

Krebs Biochemicals & Industries Ltd. announced the outcome of its Board Meeting held on December 31, 2025. The Board approved and took on record the unaudited financial results for the 34th quarter and nine months ended December 31, 2025, along with the Limited Review Report by the Auditors. The meeting commenced at 12:00 Noon and concluded at 01:30 p.m. The company's registered office is located at Kothapalli Village, Kasimkota Mandal, Anakapalli, Visakhapatnam, Andhra Pradesh - 531 031.